Sovaldi and the hepatitis C cure (2013-2014)
Gilead's Sovaldi (sofosbuvir) cured more than 90% of hepatitis C patients in 8 to 12 weeks. The roughly $84,000 per-course price triggered a national debate over drug costs.
Demand overwhelmed Gilead's supply, and insurers struggled with the cost of treating millions of patients.
Hepatitis C became the first chronic viral infection to be broadly curable, and the WHO set global elimination targets.
Both are antivirals marketed as cures for chronic liver infections. Hepatitis B is harder because the virus persists inside liver cells, so Hibsago aims for a functional cure: stopping symptoms and treating the infection without fully eradicating it.
